BIO-TECHNE Corp (TECH) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 163.70M USD | Liabilities, Current |
| Cash and equivalents | 264.71M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 216.59M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 195.74M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $163.70M | $264.71M | (m) | $216.59M | $195.74M | (m) |
| 2026-03-31 | (m) | $153.28M | $209.82M | (m) | $214.56M | $201.18M | (m) |
| 2025-12-31 | (m) | $140.43M | $172.88M | (m) | $184.61M | $205.45M | (m) |
| 2025-09-30 | (m) | $144.54M | $144.96M | (m) | $183.90M | $203.19M | (m) |
| 2025-06-30 | (m) | $175.85M | $162.19M | (m) | $206.88M | $189.45M | (m) |
| 2025-03-31 | (m) | $169.20M | $140.67M | (m) | $237.14M | $191.08M | (m) |
| 2024-12-31 | (m) | $161.26M | $177.55M | (m) | $217.94M | $188.37M | (m) |
| 2024-09-30 | (m) | $142.13M | $187.54M | (m) | $223.69M | $185.04M | (m) |
| 2024-06-30 | (m) | $159.38M | $151.79M | (m) | $241.39M | $179.73M | (m) |
| 2024-03-31 | (m) | $149.82M | $139.91M | (m) | $227.89M | $179.50M | (m) |
| 2023-12-31 | (m) | $135.23M | $130.13M | (m) | $207.45M | $180.84M | (m) |
| 2023-09-30 | (m) | $127.75M | $148.66M | (m) | $204.57M | $186.08M | (m) |
| 2023-06-30 | (m) | $128.51M | $180.57M | (m) | $218.47M | $171.64M | (m) |
| 2023-03-31 | (m) | $141.16M | $127.28M | (m) | $216.41M | $169.46M | (m) |
| 2022-12-31 | (m) | $128.40M | $164.68M | (m) | $184.76M | $160.23M | (m) |
| 2022-09-30 | (m) | $137.63M | $165.26M | (m) | $174.17M | $150.01M | (m) |
| 2022-06-30 | $441.58M | $176.02M | $172.57M | $74.46M | $194.55M | $141.12M | 2.51× |
| 2022-03-31 | $433.27M | $166.84M | $160.82M | $70.35M | $202.09M | $128.28M | 2.60× |
| 2021-12-31 | $431.88M | $154.81M | $211.84M | $67.14M | $152.90M | $121.86M | 2.79× |
| 2021-09-30 | $382.61M | $133.99M | $196.32M | $38.74M | $147.55M | $117.37M | 2.86× |
| 2021-06-30 | $376.94M | $152.28M | $199.09M | $32.46M | $145.38M | $116.75M | 2.48× |
| 2021-03-31 | $434.03M | $137.64M | $186.14M | $90.11M | $157.79M | $109.99M | 3.15× |
| 2020-12-31 | $411.19M | $117.57M | $165.53M | $117.43M | $128.24M | $106.59M | 3.50× |
| 2020-09-30 | $410.02M | $105.42M | $169.40M | $117.99M | $122.64M | $106.00M | 3.89× |
| 2020-06-30 | $393.43M | $106.67M | $146.63M | $124.27M | $122.53M | $103.15M | 3.69× |
| 2020-03-31 | $378.54M | $104.98M | $156.22M | $104.87M | $117.45M | $99.67M | 3.61× |
| 2019-12-31 | $355.70M | $104.95M | $110.29M | $133.66M | $111.75M | $95.35M | 3.39× |
| 2019-09-30 | $281.13M | $88.27M | $99.89M | $58.52M | $122.72M | $90.86M | 3.19× |
| 2019-06-30 | $303.50M | $101.98M | $100.89M | $65.15M | $137.47M | $91.05M | 2.98× |
| 2019-03-31 | $312.72M | $98.05M | $95.56M | $83.23M | $133.93M | $93.84M | 3.19× |
| 2018-12-31 | $269.82M | $87.43M | $85.89M | $70.65M | $113.28M | $90.91M | 3.09× |
| 2018-09-30 | $278.47M | $83.44M | $94.67M | $69.05M | $114.75M | $90.92M | 3.34× |
| 2018-06-30 | $302.05M | $79.51M | $121.99M | $59.76M | $120.30M | $85.65M | 3.80× |
| 2018-03-31 | $286.19M | $70.89M | $86.61M | $89.83M | $109.76M | $88.59M | 4.04× |
| 2017-12-31 | $260.88M | $111.68M | $121.46M | $40.93M | $98.50M | $68.28M | 2.34× |
| 2017-09-30 | $230.05M | $107.03M | $72.46M | $50.26M | $107.33M | $66.53M | 2.15× |
| 2017-06-30 | $274.54M | $135.52M | $91.61M | $66.10M | $116.83M | $60.15M | 2.03× |
| 2017-03-31 | $231.96M | $142.20M | $59.84M | $53.78M | $118.33M | $63.77M | 1.63× |
| 2016-12-31 | $219.86M | $120.33M | $58.94M | $56.56M | $104.37M | $66.09M | 1.83× |
| 2016-09-30 | $231.78M | $107.02M | $69.59M | $52.38M | $109.81M | $70.52M | 2.17× |
| 2016-06-30 | $189.23M | $54.15M | $64.24M | $31.60M | $93.39M | $57.10M | 3.49× |
| 2016-03-31 | $171.74M | $46.62M | $65.71M | $18.87M | $87.16M | $57.07M | 3.68× |
| 2015-12-31 | $180.06M | $35.83M | $62.45M | $51.47M | $66.14M | $58.67M | 5.03× |
| 2015-09-30 | $158.18M | $45.04M | $48.84M | $38.42M | $70.92M | $58.97M | 3.51× |
| 2015-06-30 | $180.96M | $39.77M | $54.53M | $56.39M | $70.03M | $49.58M | 4.55× |
| 2015-03-31 | $225.84M | $38.51M | $106.45M | $53.50M | $65.89M | $51.05M | 5.86× |
| 2014-12-31 | $197.15M | $44.28M | $92.97M | $46.97M | $57.21M | $52.81M | 4.45× |
| 2014-09-30 | $191.68M | $40.62M | $98.24M | $32.57M | $60.87M | $52.20M | 4.72× |
| 2014-06-30 | $411.23M | $26.39M | $318.57M | $44.79M | $47.87M | $38.85M | 15.58× |
| 2014-03-31 | $268.63M | $24.36M | $123.60M | $96.53M | $48.50M | $38.39M | 11.03× |
| 2013-12-31 | $225.16M | $22.11M | $98.40M | $88.45M | $38.31M | $39.99M | 10.18× |
| 2013-09-30 | $226.94M | $20.28M | $83.86M | $100.84M | $42.24M | $39.96M | 11.19× |
| 2013-06-30 | $371.12M | $32.08M | $163.79M | $169.15M | $38.18M | $34.88M | 11.57× |
| 2013-03-31 | $351.01M | $32.48M | $150.71M | $162.16M | $38.14M | $35.67M | 10.81× |
| 2012-12-31 | $318.28M | $21.27M | $143.29M | $142.81M | $32.19M | $37.60M | 14.97× |
| 2012-09-30 | $308.19M | $22.90M | $130.81M | $142.26M | $35.12M | $38.40M | 13.46× |
| 2012-06-30 | $304.65M | $35.75M | $116.67M | $152.31M | $35.67M | $38.28M | 8.52× |
| 2012-03-31 | $258.72M | $30.72M | $95.28M | $124.33M | $39.11M | $40.50M | 8.42× |
| 2011-12-31 | $170.10M | $14.12M | $80.99M | $56.76M | $32.35M | $40.98M | 12.04× |
| 2011-09-30 | $167.45M | $26.24M | $79.23M | $54.12M | $34.09M | $42.12M | 6.38× |
| 2011-06-30 | $176.73M | $18.19M | $77.61M | $63.20M | $35.91M | $44.91M | 9.72× |
| 2011-03-31 | $249.45M | $16.54M | $158.63M | $55.27M | $35.55M | $13.62M | 15.08× |
| 2010-12-31 | $223.09M | $13.67M | $135.88M | $58.99M | $28.23M | $13.74M | 16.32× |
| 2010-09-30 | $203.65M | $16.06M | $115.01M | $57.62M | $31.02M | $13.82M | 12.68× |
| 2010-06-30 | $169.66M | $17.02M | $94.14M | $44.67M | $30.85M | $13.74M | 9.97× |
| 2010-03-31 | (m) | (m) | $108.24M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $195.55M | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | $174.76M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $160.94M | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $166.99M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |